Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor ConferenceGlobeNewswire·Sep 21 at 08:30 PMCVKD-0.92%
Vital Farms Targets $800M Revenue as Niche Equities Show Q2 Operational DivergenceGlobal Report·Sep 15 at 10:12 AMCVKD-0.92%HCC+0.05%
Cadrenal Therapeutics CEO presents at H.C. Wainwright Global Investment ConferencePUBT·Sep 3 at 12:04 PMCVKD-0.92%
12 Health Care Stocks Moving In Tuesday's Pre-Market Sessionbenzinga_article·Sep 1 at 12:06 PMLABT-3.49%CLGN-0.26%
Regulatory Clarity and De-Risked Phase 3 Plan Support Cadrenal Buy Rating, $13 Target UnchangedTip Ranks·Sep 1 at 10:25 AMCVKD-0.92%
12 Health Care Stocks Moving In Monday's Intraday Sessionbenzinga_article·Aug 31 at 05:06 PMAEMD+2.19%AIM+0.86%
Cadrenal Maintained at Buy as Partnership-Focused Strategy Supports Unchanged $13 Price TargetTip Ranks·Aug 14 at 10:26 AMCVKD-0.92%
Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering ProcessUnusual Whales·Aug 13 at 08:17 PMCVKD-0.92%
